Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer
Open Access
- 27 April 2022
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (18)
Abstract
Significance: Pancreatic cancer is a leading cause of cancer-related death, in part due to incomplete responses to standard-of-care chemotherapy. In this study, using a combination of single-cell RNA sequencing and high-throughput proteomics, we identified the calcium-responsive protein calmodulin as a key mediator of resistance to the first-line chemotherapy agent gemcitabine. Inhibition of calmodulin led to the loss of gemcitabine resistance in vitro, which was recapitulated using a calcium chelator or Food and Drug Administration–approved calcium channel blockers (CCBs), including amlodipine. In animal studies, amlodipine markedly enhanced therapeutic responses to gemcitabine chemotherapy, reducing the incidence of distant metastases and extending survival. Hence, incorporating CCBs may provide a safe and effective means of improving responses to gemcitabine-based chemotherapy in pancreatic cancer patients.Keywords
Funding Information
- U.S. Department of Veterans Affairs (BX004903)
- U.S. Department of Veterans Affairs (BX004855)
- U.S. Department of Veterans Affairs (BX003296)
- U.S. Department of Veterans Affairs (BX005791)
- HHS | NIH | National Cancer Institute (CA236031)
- HHS | NIH | National Cancer Institute (CA255291)
- HHS | NIH | National Cancer Institute (CA211095)
- HHS | NIH | National Cancer Institute (CA242003)
This publication has 62 references indexed in Scilit:
- Calmodulin Mediates Fas-induced FADD-independent Survival Signaling in Pancreatic Cancer Cells via Activation of Src-Extracellular Signal-regulated Kinase (ERK)Journal of Biological Chemistry, 2011
- K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and functionOncogene, 2010
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205Journal of Clinical Oncology, 2010
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Clinical Oncology, 2010
- L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell linesToxicology Letters, 2010
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic CancerClinical Cancer Research, 2008
- Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca2+/calmodulinJournal of Cell Biology, 2005
- Effect of the vascular endothelial growth factor receptor‐2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude miceInternational Journal of Cancer, 2002
- Calmodulin Binds to K-Ras, but Not to H- or N-Ras, and Modulates Its Downstream SignalingMolecular and Cellular Biology, 2001